Loading...
Market
What will be Revuforj®'s market share in menin inhibitors by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports and Syndax Pharmaceuticals' financial disclosures
Story
Syndax Secures FDA Approval for Revuforj®, First Menin Inhibitor for Relapsed Acute Leukemia, Shares Rise 4.3%
Nov 18, 2024, 06:16 PM
Syndax Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its leukemia treatment, Revuforj® (revumenib). This drug is notable for being the first and only menin inhibitor approved for treating both adult and pediatric patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. The approval marks a significant achievement for Syndax, especially following previous disappointments in other acute leukemia indications. Following the announcement, shares of Syndax ($SNDX) rose by 4.3% in pre-market trading.
View original story
Similar markets
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
0-5 new countries • 25%
6-10 new countries • 25%
11-15 new countries • 25%
More than 15 new countries • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%